Roadmap to 70% Blood Pressure Control in Australia by 2030
The latest from the Newsroom
21,400
Employees
150+
Countries in which
the Group’s medicines
are distributed
20%
Over 20% of revenue from
brand-name medicines invested
in R&D each year
€ 4.9 billion
in revenue in 2021/2022
including €3.7 billion for brand-name medicines and
€1.2 billion for generic activities
4 therapeutic areas
Oncology,
Neuroscience,
Immuno-inflammation, and
Cardio-metabolism